Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Method opens pathway to new drugs and dyes

By Drug Discovery Trends Editor | September 2, 2015

The chemical structure of uncialamycin, a compound found in nature and synthesized by Rice Univ. synthetic chemist K.C. Nicolaou, is one target of a new method to simplify the manufacture of drugs and other compounds. The method is based on modifying the central three-ring structure at the bottom, known as an anthraquinone. Image: K.C. Nicolaou/Rice Univ. Rice Univ. scientists have developed a practical method to synthesize chemical building blocks widely used in drug discovery research and in the manufacture drugs and dyes.

The new method from the lab of Rice synthetic chemist K.C. Nicolaou was designed to enable the discovery and development of novel drugs to attack cancer cells and as an efficient way to create new molecular entities for biology and medicine.

The research appears in Angewandte Chemie.

The Nicolaou lab specializes in synthesizing substances found in nature that have useful properties but are too scarce to harvest from their natural sources to test, let alone use in clinical or other settings. Nicolaou is best known for being the first to synthesize the powerful anti-cancer drug taxol and more recently achieved the total synthesis of the cancer-fighting compound shishijimicin A.

The new method’s primary product is an anthraquinone, a structural motif found in many dyes (usually red) and certain medications. The anthraquinone is a simple three-ringed molecule of carbon, hydrogen and oxygen atoms. The Rice researchers discovered a practical and versatile way to synthesize amino- and methoxyphenolic anthraquinones, more complex structures needed for the development of drugs and other compounds.

The researchers are using their method to synthesize natural and designed biologically active molecules, including uncialamycin, a potent antibiotic and anti-cancer agent first discovered in a strain of streptomycete bacteria residing in a marine creature. Uncialamycin was first synthesized by the Nicolaou lab in 2007.

“This is a practical, very general method that allows us a way to make all kinds of natural products and their variations, which is important in drug discovery,” Nicolaou said. “Uncialamycin and its analogs are examples of the many applications we envision for this method.”

Nicolaou sees hope for the efficient production of uncialamycin for possible clinical use against cancer. If the drug can be successfully attached to antibodies that target tumor cells, it can invade the cells and destroy their DNA, he said.

“This is one of the most important anti-cancer agents found in nature in recent times,” he said. “The antibodies can deliver this toxin specifically to cancer cells, and they become Trojan horses. They’re sucked inside and kill the cell. So there’s a lot of interest in these compounds.”

Nicolaou said the drive and the challenges to find new drugs often results in methods with great potential. “If we can’t find a method in the chemical repertoire to solve a problem, we’re forced to create a new one,” he said. “Every molecule provides a different challenge to a synthetic chemist. We see these challenges as opportunities to develop methods that everybody can use.”

Source: Rice Univ.

• CONFERENCE AGENDA ANNOUNCED:

The highly-anticipated educational tracks for the 2015 R&D 100 Awards & Technology Conference feature 28 sessions, plus keynote speakers Dean Kamen and Oak Ridge National Laboratory Director Thom Mason.  Learn more.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE